Daily Bulletin

Business Mentor

.

  • Written by NewsServices.com

Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce that the Victorian Government has granted A$1.45M to Noxopharm collaborator, Hudson Institute of Medical Research, to fund the joint development program of novel anti-inflammatory compounds. Noxopharm’s wholly-owned subsidiary, Victoria-registered Pharmorage Pty Ltd, is named on the grant as the collaborator that will design and synthetise the compounds with the view of commercialising any promising drug candidates generated by the research. 

The research aims to identify novel drug compounds that dampen harmful excessive inflammation associated with COVID-19 infection. Should any identified drug candidates show promise of broader inflammatory indications it is anticipated that Noxopharm will investigate their commercial and scientific potential. 

Reducing excessive inflammation during COVID-19 infection is a critical part of limiting virus[1]associated hospitalisations, intensive care admissions, and deaths. In addition, mounting evidence suggests that chronic inflammation underpins post-infectious syndromes associated with long-COVID, which may impact as many as 60% of COVID-19 patients.1 Therefore, this research aims to fast-track the therapeutic development of new, targeted therapies to help manage both acute and chronic inflammation. 

Noxopharm CEO Dr Gisela Mautner, said: “Noxopharm has built a network of collaborators spanning world-renowned academic and government institutions, including Hudson Institute. We are excited the collaboration with Hudson Institute is attracting this level of non-dilutive funding. We look forward to progressing our work in inflammatory diseases with them.” The research is set to commence shortly and will continue for approximately two years. Noxopharm will continue to keep the market informed as this work progresses. 

1 Blomberg, B., Mohn, K.GI., Brokstad, K.A. et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med 27, 1607–1613 (2021). https://doi.org/10.1038/s41591-021-01433-3

Lakeba's Administrative AI Mastery: Unlocking Efficiency Across Industries

While startup success rates remain perilously low, venture studios have crafted methodologies stacking probabilities for commercialization through integrated support fine-tuned specifically for scal...

Daily Bulletin - avatar Daily Bulletin

Understanding the Real Cost of a Weighbridge or Truck Scale

Investing in a weighbridge management system makes your business more efficient, effective and compliant with regulations. But there’s more to it than that. So, read on to learn more about the compl...

Daily Bulletin - avatar Daily Bulletin

Scrap Car vs. Salvage Car: What’s the Difference?

Is the car salvage or scrap, isn't it confusing? Well, These terms may sound similar but they’re not –  It's about figuring out where these cars go.  Through this article we will make it clear what...

Daily Bulletin - avatar Daily Bulletin

Choosing the Right Professional Relocating Service In Australia Is a Big Edge

Relocating to a new place is challenging and a big adventure but the part where you have to move all your things can be hard and stressful.  The good news is there's a way to make it easier: you ca...

Daily Bulletin - avatar Daily Bulletin

How Does Personalised Packaging Influence Consumer Behaviour?

In modern commerce, personalised packaging emerges as a crucial element distinguishing brands in a saturated marketplace. This strategy extends beyond conventional packaging methodologies, infusing ...

Daily Bulletin - avatar Daily Bulletin

Ashfords Wealth Exceeds Projections, Setting a New Benchmark in Online Transactions

South Victoria, Australia - Ashfords Wealth, a prominent name in the realm of online financial platforms, has recently achieved remarkable success by surpassing its projected growth targets. This ac...

Daily Bulletin - avatar Daily Bulletin

Tomorrow Business Growth